Leap Therapeutics, INC 8-K filings

Cypherpunk Technologies announced its second quarter 2026 financial results, highlighting an increase in Zcash holdings and progress for its subsidiary Leap Therapeutics' cancer drug candidate, sirexatamab.

Cypherpunk Technologies Inc. has received a notification from Nasdaq regarding its common stock's closing bid price falling below the $1.00 minimum requirement for continued listing.

Cypherpunk Technologies Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a deficiency matter.

Cypherpunk Technologies announced its first quarter 2026 financial results, highlighting increased Zcash holdings and a strategic investment in Zcash Open Development Labs, alongside updates from its Leap Therapeutics subsidiary.

Cypherpunk Technologies Inc. announces the retirement of four board members, effective prior to the 2026 Annual Meeting of Stockholders, with no disagreements cited.

Cypherpunk Technologies Inc. reported a significant turnaround to net income in 2025, driven by a strategic pivot to privacy technology and digital asset treasury holdings, alongside progress in its biotech subsidiary.

Cypherpunk Technologies Inc. granted 5,448,157 restricted stock units to CoinXit Ltd., consolidating previous awards and fulfilling consulting agreement obligations.

Cypherpunk Technologies Inc. announced a significant expansion of its corporate treasury with the acquisition of an additional 56,418.09 Zcash (ZEC) for approximately $29 million.

Cypherpunk Technologies Inc. announced it has regained compliance with Nasdaq's minimum bid price rule and stockholders approved key proposals including a new equity incentive plan and an increase in authorized shares.

Cypherpunk Technologies Inc. has modified a warrant held by Winklevoss Treasury Investments, LLC to free up 57.18 million shares for its $200 million at-the-market equity offering program.

Cypherpunk Technologies bought an additional $18M of Zcash, lifting holdings to 233,644.56 ZEC and 1.43% of the network.

Cypherpunk Technologies Inc., formerly Leap Therapeutics, has entered into an agreement with Cantor Fitzgerald & Co. to sell up to $200 million of its common stock through an 'at-the-market' offering.

Leap Therapeutics rebrands as Cypherpunk Technologies, shifts focus to a digital asset treasury strategy with a $50 million Zcash acquisition, and appoints new leadership.

Leap Therapeutics announced final positive results from its Phase 2 DeFianCe study, demonstrating sirexatamab significantly improved progression-free and overall survival in DKK1-high colorectal cancer patients.

Leap Therapeutics closed a $58.88 million private placement led by Winklevoss Capital to fund a new digital asset treasury strategy and advance therapeutic programs.

Leap Therapeutics announced a $58.88 million private placement led by Winklevoss Capital to fund a new digital asset treasury strategy while continuing its biotech pipeline.

Leap Therapeutics, Inc. has received an additional 180-day grace period from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, extending the deadline to March 9, 2026.

Leap Therapeutics announced Q2 2025 financial results, a 75% workforce reduction, and initiated a strategic review to maximize shareholder value, despite positive clinical data for sirexatamab.

Leap Therapeutics, Inc. announced a significant workforce reduction and the wind-down of its research and development programs, including the DeFianCe clinical trial, while simultaneously exploring strategic alternatives to maximize shareholder value, despite reporting updated positive clinical data for sirexatamab in colorectal cancer.

Leap Therapeutics announced positive data from its Phase 2 DeFianCe study and its Q1 2025 financial results, alongside a strategic restructuring involving a workforce reduction.

Leap Therapeutics reports positive updated data from its Sirexatamab colorectal cancer study, showing statistically significant improvements in ORR and PFS in specific patient subgroups, and announces its fourth quarter and full year 2024 financial results.

Leap Therapeutics receives notification from Nasdaq regarding non-compliance with minimum share price requirement, triggering a potential delisting process.

Leap Therapeutics reported a 35% objective response rate in second-line colorectal cancer patients treated with sirexatamab, while a gastric cancer study did not show sufficient benefit to advance to Phase 3.

Leap Therapeutics reported its third quarter 2024 financial results, highlighted by increased R&D spending and progress in clinical trials for DKN-01 and the initiation of development for FL-501.

Leap Therapeutics has completed enrollment of 188 patients in Part B of the DeFianCe study, evaluating DKN-01 for advanced colorectal cancer.

Leap Therapeutics reported encouraging clinical trial results for its DKN-01 drug and completed a $40 million private placement to fund operations into 2026.

Leap Therapeutics held its 2024 Annual Meeting of Stockholders on July 2, 2024, where key proposals including the election of directors and ratification of the company's accounting firm were approved.

Leap Therapeutics reported its first quarter 2024 financial results, highlighted by a $40 million private placement and progress in its DKN-01 clinical trials.

Leap Therapeutics has announced a $40 million private placement to fund the expansion of its DKN-01 clinical trials and extend its cash runway into Q2 2026.

Leap Therapeutics reported promising clinical data for its DKN-01 drug in cancer trials and its year-end 2023 financial results.